SHR-A1811 for recurrent ovarian cancer (platinum-sensitive)
Treatments studied
Part of Cancer, Hormones & metabolism, Women’s health & pregnancy clinical trials.
This trial tests a new drug, SHR-A1811, for ovarian cancer that came back after responding well to platinum chemo. It is for people with BRCA mutations or HRD positive status who have already tried a PARP inhibitor.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have a type of ovarian, fallopian tube, or primary peritoneal cancer (not mucinous)
- You have had 1 to 3 rounds of platinum chemo, and your cancer came back at least 6 months after the last round
- You have either a BRCA1/2 gene mutation or are HRD positive (tested by your doctor)
- You have taken a PARP inhibitor before (like olaparib, niraparib, or rucaparib)
- You are between 18 and 75 years old, generally able to care for yourself (ECOG 0-1), and have good organ function
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial tests a new targeted drug, SHR-A1811, combined with chemotherapy for women whose ovarian cancer has returned but still responds to platinum-based drugs. The goal is to see if the combination works better than chemotherapy alone.
This trial tests a new targeted drug (SHR-A1811) against standard chemotherapy for ovarian cancer that no longer responds to platinum drugs. It's for people whose tumors have a specific protein called HER2, and who have had limited prior treatments after platinum resistance.
This trial tests a new drug called SHR-A1811 for ovarian cancer. It may help people whose cancer can be measured on scans and who are still well enough to do daily activities.
This trial tests a new targeted drug, SHR-A1921, given alone or with chemotherapy (carboplatin) for people with ovarian cancer that has come back or spread. It aims to see if this combination works better than standard treatments.
This study tests a new drug called SHR-A1921 for people with ovarian cancer that no longer responds to platinum chemotherapy. The goal is to see if it can shrink tumors or slow the cancer's growth.
This trial tests a new combination of drugs (trastuzumab rezetecan and carboplatin, with or without bevacizumab) against standard chemotherapy for women with recurrent ovarian, fallopian tube, or primary peritoneal cancer. It’s for those who have already had platinum-based chemo and a PARP inhibitor, and whose cancer came back after a treatment-free interval of at least 6 months.
Hear when a new Ovarian cancer trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.